Please assess the completion status of the following clinical trial:

Trial Title: ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed stage I or II primary operable breast cancer~  * Surgery planned within next 1-4 weeks~* Hormone receptor status:~  * Estrogen receptor positive or unknown~ * No known estrogen receptor negative tumor~ * Unknown progesterone receptor status eligible~PATIENT CHARACTERISTICS:~Age:~* Any age~Sex:~* Female~Menopausal status:~* Premenopausal or postmenopausal~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* No bleeding diathesis not compatible with an IM depot injection~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective non-hormonal contraception during and for 2-3 months after study~* No other prior or concurrent malignancy except adequately treated basal cell carcinoma of the skin or cancer of the uterine cervix~* No psychological, familial, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* At least 2 months since prior ICI 182780~Radiotherapy:~* No prior radiotherapy to primary tumor~Surgery:~* See Disease Characteristics~Other:~* No other concurrent preoperative therapy for breast cancer

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).